Search research articles
Contact Us
Filters
Showing results (621-630 of 651) with videos related to
Page
of 66
Sort By:
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
The European Respiratory Journal
|
July 9, 2016
Defining a standard set of patient-centred outcomes for lung cancer
Kimberley S Mak, Annelotte C M van Bommel, Caleb Stowell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung Cancer
Geoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Blood Cancer Discovery
|
September 13, 2021
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Victoria E Wang, Bradley W Blaser, Ravi K Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Page
of 66
Search research articles
Search
Showing results (621-630 of 651) with videos related to
Sort By:
Page
of 66
ESMO Open
|
December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]
M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
The European Respiratory Journal
|
July 9, 2016
Defining a standard set of patient-centred outcomes for lung cancer
Kimberley S Mak, Annelotte C M van Bommel, Caleb Stowell, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 20, 2021
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
Angel Qin, Songzhu Zhao, Abdul Miah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 17, 2024
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients with Small Cell Lung Cancer
Daniel Morgensztern, Neal Ready, Melissa L Johnson, et al.
Journal of Hematology & Oncology
|
May 18, 2022
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 14, 2023
Germline <i>EGFR</i> Mutations and Familial Lung Cancer
Geoffrey R Oxnard, Ruthia Chen, Jennifer C Pharr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer
Hossein Borghaei, David Balli, Luis G Paz-Ares, et al.
Blood Cancer Discovery
|
September 13, 2021
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Victoria E Wang, Bradley W Blaser, Ravi K Patel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Page
of 66